Tech Company Financing Transactions

Prellis Biologics Funding Round

Prellis Biologics closed a $35 million Series C financing round on 8/10/2022. Investors included Avidity Partners, Celesta Capital and Khosla Ventures.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

900 Indiana St.
San Francisco, CA 94107
USA

Phone

Undisclosed

Website

www.prellisbio.com

Email Address

Not Recorded

Overview

At Prellis Biologics, we are driven by our vision of a world where functional human tissues can be created on demand in a laboratory setting.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Melanie Matheu

        

Controller

Matthew Niemiec

        

VP - Bus. Development

Diana Bogorodskaya

        

VP - Engineering

Erik Busby

        

Browse more venture capital transactions:

Prev: 8/10/2022: Convertedin venture capital transaction
Next: 8/10/2022: Xeltis venture capital transaction

Share this article

Where The Data Comes From

We do our best to document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary